REVIEW
|
doi:10.20944/preprints202307.1468.v1
Subject:
Medicine And Pharmacology,
Hematology
Keywords:
CLL; atypical CLL; CD5; CD23; CLL differential diagnosis.
Online: 21 July 2023 (09:07:06 CEST)
CASE REPORT
|
doi:10.20944/preprints202406.1511.v1
Subject:
Medicine And Pharmacology,
Hematology
Keywords:
ibrutinib; 17p deletion; kidney biopsy; renal lymphomatous infiltration; monoclonal b cell lymphocytosis (mbl); complications of cll; venetoclax; chronic lymphocytic leukemia (cll); cll treatment; renal involvement in cll
Online: 24 June 2024 (07:41:28 CEST)
ARTICLE
|
doi:10.20944/preprints202408.1596.v1
Subject:
Medicine And Pharmacology,
Hematology
Keywords:
Chronic lymphocytic leukemia (CLL); Signal Transduction; Cytokines; T Cells
Online: 21 August 2024 (16:59:32 CEST)
REVIEW
|
doi:10.20944/preprints202304.0843.v2
Subject:
Medicine And Pharmacology,
Hematology
Keywords:
CLL, Zanubrutinib, BTK inhibitors, efficacy, safety, chronic lymphocytic leukemia
Online: 22 May 2023 (16:15:16 CEST)
ARTICLE
|
doi:10.20944/preprints202101.0330.v1
Subject:
Medicine And Pharmacology,
Immunology And Allergy
Keywords:
germline; rare variant; cancer; lymphoid; B-cell; lymphomal; CLL; driver; prognosis
Online: 18 January 2021 (12:14:32 CET)
ARTICLE
|
doi:10.20944/preprints202310.1792.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
RRAS2; Somatic mutations; 3'-untranslated region; Chronic Lymphocytic Leukemia (CLL); Clinical implications
Online: 27 October 2023 (12:17:15 CEST)
ARTICLE
|
doi:10.20944/preprints202309.1417.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
R-RAS2; RAS; GTPases; chronic lymphocytic leukemia; B-CLL; mouse model; ibrutinib; venetoclax; new therapies; cancer treatment
Online: 21 September 2023 (12:04:56 CEST)
ARTICLE
|
doi:10.20944/preprints202407.2194.v1
Subject:
Medicine And Pharmacology,
Hematology
Keywords:
microRNA; prognosis; CLL; time to first treatment (TTFT); IGVH mutations, del11q, del17p; Beta-2-microglobulin (B2M); Rai stage; NOTCH1
Online: 26 July 2024 (14:16:36 CEST)
REVIEW
|
doi:10.20944/preprints202112.0282.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Acalabrutinib; Bruton’s tyrosine kinase; BTK; CLL; Covalent inhibitors; COVID-19; Ibrutinib; Non-covalent inhibitors; Fenebrutinib; MK1026; Pirtobrutinib; Spebrutinib; Tirabrutinib; Zanubrutinib
Online: 16 December 2021 (16:13:54 CET)